68 -6 (68) 2024 - Rizaeva M.J. - ATRIURETIC PEPTIDE AS A PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH CORONARY HEART DISEASE

ATRIURETIC PEPTIDE AS A PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH CORONARY HEART DISEASE

Rizaeva M.J. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Bukhara branch of the Republican Scientific Center for Emergency Medical Care Uzbekistan

Resume

Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice and occurs in 1-2% of the population. AF is considered to be an independent risk factor for cardiovascular disease. Thus, many studies will demonstrate that AF is associated with increased levels of N-terminal fragment of brain natriuretic peptide (NT-proBNP). Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are cardiac hormones that regulate body fluid volume and blood pressure (BP). The leading stimulus for the synthesis and secretion of BNP and ANP is an increase in the tension of the myocard. An increase in intracavitary pressure, volume overload, and dilation of the heart cavities lead to an increase in NUP levels [1].

Key words: Atrial natriuretic peptide, coronary heart disease, persistent form of atrial fibrillation, progression factors.

First page

398

Last page

401

For citation:Rizaeva M.J. - ATRIURETIC PEPTIDE AS A PREDICTOR OF ATRIAL FIBRILLATION IN PATIENTS WITH CORONARY HEART DISEASE//New Day in Medicine 6(68)2024 398-401 https://newdayworldmedicine.com/en/new_day_medicine/6-68-2024

List of References

1. Nishikimi T. Do plasma levels of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) increase in diastolic dysfunction as well as in systolic dysfunction? //Circ J 2012;76(11):2540-1.
2. Wei G., Yaqi R., Ningfu W., et al. N-terminal prohormone B-type natriuretic peptide and cardiovascular risk in stable coronary artery disease: a meta-analysis of nine prospective studies. //Rev Cardiovasc Med 2013;14(2-4):e92-8.
3. Van der Zee P.M., Verberne HJ, et al. Relation of N-terminal pro B-type natriuretic peptide levels after symptom-limited exercise to baseline and ischemia levels. //Am J Cardiol 2009;103(5):604-10.
4. Aldhoon B., Melenovskэ V., Peichl P., et al. New insights into mechanisms of atrial fibrillation. //Physiol Res 2010;59(1):1-12.
5. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. //JAMA. 2004;291:1720-1729.
6. Wozakowska-Kapłon B., Opolski G., Janion M., et al. Plasma concentration of atrial natriuretic peptide is related to the duration of atrial fibrillation in patients with advanced heart failure. //Kardiol Pol 2004;61(12):513-21.
7. Wozakowska-Kaplon B. Changes in plasma natriuretic peptide levels in patients with atrial fibrillation after cardioversion. //Int J Cardioln 2010;144(3):436-7.
8. Kurosaki K., Tada H., Hashimoto T. Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. //Circ J 2007;71:313-20.
9. Подзолков Валерий Иванович, Тарзиманова Аида Ильгизовна, Лория Иракли Жанович (2015). Изменение уровня натрийуретических пептидов у пациентов с фибрилляцией предсердий при лечении антиаритмическими препаратами. //Рациональная фармакотерапия в кардиологии 2015;11(4):365-370.
10. Khand A.U., Chew P.G., Douglas H., et al. The effect of carvedilol on B-type natriuretic Peptide and cardiac function in patients with heart failure and persistent atrial fibrillation. //Cardiology 2015;130(3):153-8.
11. Ruggiero F., Santini L., Gallagher M.M., et al. Changes in brain natriuretic peptide level as a predictor of AF recurrence after electrical cardioversion //Minerva Cardioangiol. 2011;59(2):135-138.
12. Romano S., Di Mauro M., Fratini S., et al. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides //Cardiovasc. Diabetol. – 2010;16(89):3-8.
13. Наумов Д. В., Ахмедов В. А., Долгих В. Т., Кулаева Л. А. (2011). Натрийуретический пептид В-типа как предиктор пароксизмов фибрилляции предсердий у пациентов с метаболическим синдромом. //Байкальский медицинский журнал, 2011;107(8):25-27.
14. Rizaeva M.Z. (2022). The clinical course of atrial fibrillation in patients with coronary heart disease. //European journal of molecular medicine, 2022;2(1).
15. Baratova M.S., Rizaeva M.J. (2022). Diagnosis of paroxysmal rhythm disturbances in young people with arterial hypertension. //NeuroQuantology, 2022;20(10):5542.
16. Jumaevich B.K., Jamolovna R.M. (2024). The role of predictors in the formation of thrombosis in atrial fibrillation. //Journal of biomedicine and practice 2024;9(2).

    file

    download